PARIS, Aug 3 (Reuters) – French drugmaker Sanofi (SASY.PA) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (TBIO.O), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Chief Executive Paul Hudson said.Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.
Dubai leveraged its strategic coastline to become a global trade hub, exporting “access itself” through…
Keturah Reserve launches final sales phase as 2025 data reveals AED86B capital gains and major…
The UK economy contracted again in late 2025, with weaker services output fuelling expectations of…
U.S. lawmakers are raising alarms over Nvidia’s AI chip exports to China, warning that allowing…
The historic occasion recognized and immortalized Adesina’s name, leadership, contributions to Africa, and his visionary…
Record 215,700 annual sales worth AED 686.8 billion underscore city's position as a premier global…